Vontobel Holding Ltd. Aldeyra Therapeutics, Inc. Transaction History

Vontobel Holding Ltd.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Jun 03, 2024	SELL	$6.11 - $8.16 $132,232 - $176,598	-21,642 Reduced 58.17%	15,560 $103,000
Q3 2023 Oct 10, 2023	SELL	$6.11 - $8.16 $132,232 - $176,598	-21,642 Reduced 58.17%	15,560 $103,000
Q2 2023 Jun 03, 2024	BUY	$7.11 - $11.89 $169,004 - $282,625	23,770 Added 176.97%	37,202 $312,000
Q2 2023 Jul 24, 2023	BUY	$7.11 - $11.89 $169,004 - $282,625	23,770 Added 176.97%	37,202 $312,000
Q1 2023 Jun 03, 2024	BUY	$5.77 - $9.93 $77,502 - $133,379	13,432 New	13,432 $133,000
Q1 2023 Apr 12, 2023	BUY	$5.77 - $9.93 $19,462 - $33,493	3,373 Added 33.53%	13,432 $133,000
Q4 2022 Feb 14, 2023	BUY	$5.08 - $7.09 $51,099 - $71,318	10,059 New	10,059 $70,000

117

36.4M

196K

142K

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $279M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

Get notified when there are updates to the investment portfolio of Vontobel Holding Ltd., based on Form 13F filings with the SEC.

Stay updated on Vontobel Holding Ltd. with notifications on news.